STOCK TITAN

WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Cranford, New Jersey--(Newsfile Corp. - May 19, 2023) - WBB Research Institute (WBBRI) hosted a Demi-Colton Virtual Salon on the need for a global response to Candida auris and other deadly pathogens. Antimicrobial resistant C. auris is becoming a major public health threat and is found in over 30 countries causing outbreaks in hospitals, nursing homes, and other healthcare settings. It or another emerging antimicrobial resistant pathogen will likely be the cause of the next global pandemic. Scynexis (NASDAQ: SCYX) and T2 Biosystems (NASDAQ: TTOO) were two of the public companies that participated in the webinar, which highlighted the need for increased collaboration between academia, government agencies and the private sector to accelerate the development and use of rapid blood diagnostics and novel therapeutics.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Antimicrobial resistant C. auris is becoming a major public health threat
  • The webinar highlighted the need for increased collaboration between academia, government agencies and the private sector.
  • To accelerate the use of rapid from whole blood diagnostics and novel therapeutics.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/166755_figure1_550.jpg

Click image above to view full announcement.


WBB Securities
The WBB Research Institute is a research organization, founded by WBB Securities. The Institute focuses on emerging critical issues in healthcare that threaten to have profound impact. WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused on the life sciences. WBB Securities is registered with the SEC as a broker-dealer, a FINRA member firm, and a Registered Investment Advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high-net-worth clients.

Demy-Colton
Demy Colton is a leader in biotech and life science events, with over 20 years of experience connecting leaders of innovative biotech companies with key stakeholders, investors, and advisors, we create ideal environments to examine and address opportunities and challenges in today's biotech industry.www.demy-colton.com.

Contacts:

Fatima Bohorquez
(908) 518 7610
Fatima.Bohorquez@wbbsec.com

Source: WBB Securities

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/166755

SCYNEXIS, Inc.

NASDAQ:SCYX

SCYX Rankings

SCYX Latest News

SCYX Stock Data

68.71M
37.27M
2.84%
48.35%
2.59%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
JERSEY CITY

About SCYX

scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.